Literature DB >> 24460438

Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia.

Vikas Pathak1, Judy M Kuhn, Carolyn Durham, William K Funkhouser, David C Henke.   

Abstract

Cryptogenic organizing pneumonia is an idiopathic form of organizing pneumonia (also known as bronchiolitis obliterans organizing pneumonia). Because cryptogenic organizing pneumonia is considered an inflammatory disease, it characteristically responds to the broad-spectrum antiinflammatory corticosteroids, although relapse is common on discontinued use. Additionally, long-term use of corticosteroids has many side effects. In severe cases in which corticosteroids have failed, either cytotoxic therapy or macrolide therapy is used. Because of the toxicity and adverse effects of cytotoxic therapy (e.g., cyclophosphamide), this therapy option cannot be used long term in refractory cases. Macrolide therapy has been shown to be an effective antiinflammatory agent that is relatively safe when used on a long-term basis in patients with cryptogenic organizing pneumonia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24460438     DOI: 10.1513/AnnalsATS.201308-261CR

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  13 in total

1.  Seven patients with cryptogenic organizing pneumonia succesfully treated with clarithromycin.

Authors:  Fatma Ciftci; Özlem Özdemir Kumbasar
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

2.  Organizing pneumonia revisited: insights and uncertainties from a series of 67 patients.

Authors:  A L Vieira; A Vale; N Melo; P Caetano Mota; J M Jesus; R Cunha; S Guimarães; C Souto Moura; A Morais
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

3.  A 12-week combination of clarithromycin and prednisone compared to a 24-week prednisone alone treatment in cryptogenic and radiation-induced organizing pneumonia.

Authors:  Nicolas Petitpierre; Vincent Cottin; Sylvain Marchand-Adam; Sandrine Hirschi; Dominique Rigaud; Isabelle Court-Fortune; Stéphane Jouneau; Dominique Israël-Biet; Anita Molard; Jean-François Cordier; Romain Lazor
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

4.  Pulmonary Toxicities of Immunotherapy.

Authors:  Mehmet Altan; Linda Zhong; Vickie R Shannon; Ajay Sheshadri
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  A case of bronchiolitis obliterans organizing pneumonia in an HIV-infected Korean patient successfully treated with clarithromycin.

Authors:  In Young Jung; Yong Duk Jeon; Mi-Young Ahn; Eunkyong Goag; EunHye Lee; Hea Won Ahn; Jin Young Ahn; Nam Su Ku; June Myung Kim; Jun Yong Choi
Journal:  BMC Infect Dis       Date:  2015-07-23       Impact factor: 3.090

6.  Cryptogenic organizing pneumonia-Results of treatment with clarithromycin versus corticosteroids-Observational study.

Authors:  Elżbieta Radzikowska; Elżbieta Wiatr; Renata Langfort; Iwona Bestry; Agnieszka Skoczylas; Ewa Szczepulska-Wójcik; Dariusz Gawryluk; Piotr Rudziński; Joanna Chorostowska-Wynimko; Kazimierz Roszkowski-Śliż
Journal:  PLoS One       Date:  2017-09-25       Impact factor: 3.240

7.  Effectiveness of Combined Therapy with Pirfenidone and Erythromycin for Unclassifiable Interstitial Pneumonia Induced by HTLV-1-associated Bronchioloalveolar Disorder (HABA).

Authors:  Naoko Yokohori; Akitoshi Sato; Mizue Hasegawa; Hideki Katsura; Kenzo Hiroshima; Tamiko Takemura
Journal:  Intern Med       Date:  2017-01-01       Impact factor: 1.271

Review 8.  Late effects of blood and marrow transplantation.

Authors:  Yoshihiro Inamoto; Stephanie J Lee
Journal:  Haematologica       Date:  2017-02-23       Impact factor: 9.941

9.  A long-term retrospective study of patients with biopsy-proven cryptogenic organizing pneumonia.

Authors:  Ying Zhou; Lei Wang; Mei Huang; Jingjing Ding; Hanyi Jiang; Kefeng Zhou; Fanqing Meng; Yonglong Xiao; Hourong Cai; Jinghong Dai
Journal:  Chron Respir Dis       Date:  2019 Jan-Dec       Impact factor: 2.444

10.  Clarithromycin mitigates radiation pneumonitis in patients with lung cancer treated with stereotactic body radiotherapy.

Authors:  Atsuya Takeda; Yuichiro Tsurugai; Naoko Sanuki; Tatsuji Enomoto; Masaharu Shinkai; Tomikazu Mizuno; Yousuke Aoki; Yohei Oku; Takeshi Akiba; Yu Hara; Etsuo Kunieda
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.